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Abstract Magnetic resonance spectroscopy (MRS) is the
only non-invasive, non-radiation-based technique for
investigating the metabolism of living tissue. MRS of
protons (1H-MRS), which provides the highest sensitivity
of all MR-visible nuclei, is a method capable of detecting
and quantifying specific cardiac biomolecules, such as
lipids and creatine in normal and diseased hearts in both
animal models and humans. This can be used to study
mechanisms of heart failure development in a longitudinal
manner, for example, the potential contribution of myo-
cardial lipid accumulation in the context of ageing and
obesity. Similarly, quantifying creatine levels provides
insight into the energy storage and buffering capacity in the
heart. Creatine depletion is consistently observed in heart
failure independent of aetiology, but its contribution to
pathophysiology remains a matter of debate. These and
other questions can in theory be answered with cardiac
MRS, but fundamental technical challenges have limited
its use. The metabolites studied with MRS are much lower
concentration than water protons, requiring methods to
suppress the dominant water signal and resulting in larger
voxel sizes and longer scan times compared to MRI.
However, recent technical advances in MR hardware and
software have facilitated the application of 1H-MRS in
humans and animal models of heart disease as detailed in
this review.
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Introduction
Heart failure, defined as the inability of the heart to supply
sufficient blood flow to meet the needs of the body, is a
major societal burden due to its high prevalence, poor
prognosis and cost. In the United Kingdom, it affects at least
one person out of 100, and this number is anticipated to rise
in the next few years [1]. Despite intensive work, the
pathogenesis of this multifactorial syndrome—which
includes changes in metabolism—is still poorly understood.
Every day, the heart consumes—in the form of adeno-
sine triphosphate (ATP)—more energy relative to its
weight than any other organ [2–4]. To meet its energy
demand, a healthy heart predominantly oxidises free fatty
acids (FFA) and glucose.
A long-standing hypothesis suggests that the failing heart
is energy-starved. However, until the past two decades, this
concept—and cardiac metabolism in general—has not
really been accessible, mostly due to the lack of techniques
to assess metabolic processes of the whole heart in vivo.
The advent of surgically and genetically modified (small)
animal models, combined with the development of more
sophisticated research tools, has sparked a renewed interest
in cardiac (energy) metabolism (see for example [5]).
Cardiac Magnetic Resonance (CMR) Imaging has
become a clinically well-established tool to assess cardiac
morphology, function and viability. However, metabolic
processes are not accessible to this technique. Conversely,
Magnetic Resonance Spectroscopy (MRS) is a technique
that allows non-invasive biochemical analysis of living
tissue. Unlike other imaging modalities such as PET or
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SPECT, it has the combined advantages of inherently
providing molecular information, being free of ionising
radiation, and not requiring administration of external
tracers or contrast agents.
MRS is based on the same basic physical principles and
uses similar equipment as MRI and can provide informa-
tion on metabolites containing nuclei with a (net nonzero)
nuclear spin. The most widely studied nuclei are phos-
phorus (31P), hydrogen (1H) and to a lesser extent sodium
(23Na). The advent of hyperpolarisation techniques (DNP–
dynamic nuclear polarisation) has opened a new field for
carbon-13 (13C)-MRI/MRS. Each of these nuclei assesses
different aspects of cardiac metabolism as illustrated in
Fig. 1. 31P-MRS gives insight into high-energy phosphate
metabolism (i.e., PCr, ATP and Pi) and intracellular pH.
23Na can detect changes in intracellular and extracellular
myocardial sodium content (ion homoeostasis). Due to the
recent development of DNP, which increases the sensitivity
by up to 5 orders of magnitude, 13C holds great potential to
study multiple metabolic pathways such as glycolysis, tri-
carboxylic acid (TCA) cycle or b-oxidation in the myo-
cardium. However, it is limited by the very short half-life
time of the hyperpolarised nucleus and the need to inject
supra-physiological concentrations of labelled substrate.
Moreover, its clinical applicability and value for the char-
acterisation of human hearts has yet to be demonstrated.
The proton (1H) is the nucleus with the highest
NMR sensitivity and natural abundance in living tissue
([99.9 %). Therefore, 1H-MRS can potentially become a
powerful technique as it can detect and quantify a variety
of myocardial metabolites including lipids, taurine, carni-
tine and total creatine (Fig. 2). Lactate has also been
detected in the hypoxic perfused rat heart [6, 7]. However,
due to its low concentration and overlapping frequency
range with the lipid resonance, its detection relies on
excellent spectral resolution and/or the use of techniques to
suppress the lipid signal. Finally, deoxy-/oxy-myoglobin
resonances have been used to quantify myocardial oxygen
availability ex vivo [8] or in vivo during high work states
[9–11].
In vivo, 1H-MRS is mainly used to provide a window
into cardiac metabolism at two different levels. Firstly,
lipid (triglyceride) content of the heart is highly dynamic
and myocardial lipid overload has been implicated in the
pathophysiology of cardiac disease. Thus, measuring lipids
will help to better understand their role in the healthy and
diseased heart. Secondly, the measurement of total crea-
tine, a crucial actor in the creatine kinase system, gives an
insight into high-energy phosphate transport and storage.
However, 1H-MRS is technically challenging and, up to
now, necessitates specialist expertise and a dedicated set-
up, which are the main reasons why the application of this
otherwise versatile technique is still limited in clinical
cardiology—despite considerable potential.
Clinical and preclinical studies are complementary for
studying cardiac metabolism in the healthy and diseased
Fig. 1 Schematic
representation of a myocyte
representing the various aspects
of cardiac metabolism that are
accessible to MRS. Metabolites
and flux measured by 13C-MRS
are highlighted in red; by 31P-
MRS, in purple; and by 1H-
MRS, in blue, respectively. FFA
free fatty acids; FAT fatty acid
transporter; GLUT glucose
transporter; AcCoA acetyl-
coenzyme A; TCA tricarboxylic
acid cycle; ANT adenine
nucleotide translocase; CK
creatine kinase; ETC electron
transport chain; NADH
nicotinamide adenine
dinucleotide; FADH2 flavin
adenine dinucleotide; Cr
creatine; PCr phosphocreatine;
CrT creatine transporter
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heart. We will therefore initially provide a brief overview
of methodological challenges and solutions, following
which we will review the major findings in lipid and cre-
atine metabolism in both patients and animal models using
1H-MRS. We will conclude with an outlook into future
directions.
Methodological considerations
Since the acquisition of the first 1H-MRS spectrum of an
intact (perfused) rat heart in 1984 [12], it took 10 more
years until the first human heart spectra were published
[13]. Compared to the application of cardiac imaging,
surprisingly, very little has since then been reported on the
application of this technique in clinical and preclinical
CMR. The main reason why 1H-MRS has not yet fulfilled
its promise in clinical cardiology is related to its funda-
mental methodological challenges: (1) the metabolites
studied with MRS are present in concentrations that are
several orders of magnitude lower (typically in the mmol/l
range) than those of water protons (present in concentra-
tions of *85 mol/l in tissue), resulting in larger voxel sizes
and longer scan times compared to MRI as many signal
averages are needed to obtain a sufficient signal-to-noise
ratio (SNR). (2) The influence of cardiac and respiratory
motion has to be minimised as this can negatively impact
on the SNR. (3) The dominant water signal needs to be
sufficiently suppressed to detect the weak metabolite sig-
nals. (4) Efficient water suppression and separation of the
various metabolites in the spectrum require an excellent
homogeneity of the static magnetic field, which is difficult
to achieve especially in heterogeneous tissues (i.e., myo-
cardium, blood, skeletal muscle, lungs) and is further
hampered by the effect of motion. (5) The post-processing
and data analysis is technically demanding and requires the
consideration and correction of various experimental
parameters if absolute metabolite concentrations are to be
obtained. This list indicates that 1H-MRS is a technically
complex method and requires a committed, interdisciplin-
ary team of physicists, biochemists and clinical cardiolo-
gists to overcome these challenges. The technical
requirements for a successful application of 1H-MRS in
vivo are summarised below.
Hardware and MR setup
Cardiac 1H-MRS studies use the same hardware (i.e.,
magnet, gradient and radiofrequency (RF) coils) as any
cardiac MRI examination. A higher static magnetic field
Fig. 2 Schematic representation of single-voxel techniques that have
been used to measure cardiac metabolites in the interventricular
septum of mice (a, a0) and human (b, b0) hearts. a A cardiac- and
respiratory-gated double spin-echo sequence (PRESS) was used to
localise a 2 9 1 9 1 mm3 voxel in the myocardium of a C57BL/6J
mouse (256 averages were applied). b A cardiac-gated stimulated
echo sequence (STEAM) was applied 35 times over 5 breath-hold of
approximately 16 s to acquire the signal from a 32 9 18 9 22 mm3
voxel in the human heart of an healthy volunteer. The main
resonances are assigned as residual (1) water, 4.7 ppm; (2) creatine
(–CH2), 3.88 ppm; (3) taurine, 3.39 ppm; (4) trimethyl-ammonium
compounds, 3.21 ppm; (5) creatine (–CH3), 2.99 ppm; (6) triglycer-
ides CaH2COO, 2.21 ppm, (7) triglycerides (CH2–CH = CH–CH2),
1.99 ppm; (8) triglycerides (–CH2)n, 1.28 ppm; (9) triglycerides
(CH3), 0.84 ppm. TE echo time; TM mixing time; FID free induction
decay; RF radiofrequency pulses.—Human spectrum (b0) courtesy of
Dr B. Rial
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strength not only increases the signal-to-noise ratio of the
experiment, but also benefits the spectral resolution.
Human 1H-MRS studies have been possible on MR sys-
tems with a magnetic field strength of 1.5 and 3 Tesla [13–
16], while we were the first to report on this technique in
the mouse heart in vivo using an 11.7 Tesla magnet [17].
Preclinical CMR studies in small and large animal models
have the additional complexity of anaesthesia and guar-
anteeing animal welfare during the MR examination.
Given the location of the heart inside the body, dedi-
cated localisation techniques are required to obtain the
metabolite signals from the myocardium only. The most
commonly used single-voxel techniques, based on either a
double spin-echo method (PRESS–Point-RESolved Spec-
troscopy sequence) [18] or stimulated echo sequence
(STEAM–STimulated Echo Acquisition Mode sequence)
[19], are schematically depicted in Fig. 2a, b respectively.
Both require the application of three RF-pulses, each of
which excites a plane orthogonal to each other. The
resulting volume (i.e., voxel), from which the metabolite
signals originate, is defined by the intersection of the three
planes. More details about these pulse sequences can be
found elsewhere [20, 21]. The voxel for cardiac MRS is
typically placed in the inter-ventricular septum to avoid
contamination of the spectrum with signals arising from
pericardial fat. Metabolites in the blood have been shown
not to contribute significantly to the final spectrum [14, 15,
17]. The MRS sequence is synchronised with the heartbeat,
using the ECG signal. Multiple methods have been used to
control for respiratory motion, including breath-holds,
respiratory gating [22] or post-acquisition processing [23].
The main advantage of the breath-hold technique is that it
does not require a complicated set-up [24]. While myo-
cardial lipids can even be reproducibly measured within a
single breath-hold [15], multiple breath-holds, if required,
may become uncomfortable for patients and can lead to
irreproducible position of the diaphragm [25]. Other
motion-compensation techniques, including the use of a
pressure belt registering the movements of the chest [16],
the detection of the variation of the ECG amplitude during
respiratory events [25] and, more recently, the application
of navigator signals, which sense the displacement of the
diaphragm [26, 27], have shown a good reproducibility.
Suppression of the dominant water signal is preferred
even if modern analogue-to-digital converters (ADCs)
provide a sufficient dynamic range to digitally resolve the
weak metabolite and the large water signal simultaneously.
However, the presence of a 3–5 order of magnitude
stronger water resonance can create baseline distortions in
the spectrum and render metabolite quantification unreli-
able, especially for metabolites with a chemical shift close
to that of water (such as the methylene resonance of cre-
atine). Water suppression schemes, such as chemical shift
selective saturation [28], or saturation enhanced through T1
effects [29], are therefore typically applied prior to the
spectroscopic sequence.
Depending on the spectral resolution and on the hard-
ware used, a typical 1H-MRS study required between 15
and 30 min, which can potentially be a problem in unstable
patients. In preclinical studies, a careful monitoring of
cardiorespiratory function and body temperature is essen-
tial during the MRS-experiment.
Post-processing and quantification
Unlike in the case of (cardiac) MR images, the information
contained in an MR spectrum is less intuitive, except when
there is an obvious deviation from the norm by the pres-
ence/absence of a resonance in the spectrum. Hence,
computational fitting of the data either in the acquisition
(i.e., time) domain or in its Fourier (i.e., frequency) domain
is required to obtain a quantitative measure of a metabolite
signal. This process is hampered not only by the low sig-
nal-to-noise in the data, but also by an imperfect model
function used to approximate the data. Motion, magnetic
field inhomogeneities, residual eddy currents (caused by
fast switching magnetic field gradients required for water
suppression and/or localisation) and a rolling baseline in
the spectra (resulting from the residual water) may place
additional constraints on the quantitative analysis of 1H-
MR spectra and may make robust fitting very difficult.
Frequency- and phase correction of each acquisition prior
to averaging, based on either the residual water signal or
the lipid signal, have been shown to improve at least the
line-shape and the SNR.
Absolute quantification, that is, the measurement of
metabolite concentrations in mmol/l requires the use of a
concentration standard (external or internal), and the cor-
rection of all parameters intervening in absolute quantifi-
cation, such as the influence of relaxation/saturation,
RF-pulse inhomogeneity, RF-coil sensitivity etc. It is
therefore more common to acquire one water-suppressed
and one water-unsuppressed spectrum from the same
location in the myocardium and to quantify the metabolites
relative to the water content as an internal reference. This
approach compensates for any hardware influence, such as
RF-profile or eddy currents, but will fail if the tissue water
content is altered. Most of the applications reported in the
following two sections have used this semi-quantitative
approach.
Lipid metabolism
Since the first detection of myocardial lipids in vivo in the
human heart [13] in 1994, 1H-MRS has been shown to be a
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reliable and reproducible technique to quantify lipid con-
tent. As illustrated in Fig. 2, multiple lipid resonances can
be observed in a typical cardiac 1H-spectrum, which are
attributable mostly to the methyl and methylene resonances
of triglycerides, although contribution from other lipids
such as cellular phospholipids cannot be excluded [30].
The methylene resonance at 1.28 ppm is commonly used
for quantification due to the higher concentration of
methylene protons in fat and referenced to the (unsup-
pressed) water signal from the same region of interest.
Validation on animal hearts showed a good correlation
between spectroscopic and standard biochemical mea-
surements [16]. Moreover, the technique is ideally suited
for longitudinal studies due to its high long-term repro-
ducibility rate; a coefficient of variation of only 5 % was
observed by Reingold et al. [31] over a 90-day period. The
myocardial lipid pool is highly dynamic, and in physio-
logical conditions, the myocardial triglyceride (Tg) content
can vary significantly. Therefore, it is important to under-
stand the possible sources of physiological variations in the
normal heart before describing the role of abnormal lipid
levels in the disease state. We will focus on the most
common pathologies affecting the heart, such as obesity
and type 2 diabetes mellitus, myocardial infarction, car-
diomyopathy and heart failure (HF).
Physiological variations of Tg in the healthy heart
In healthy non-obese individuals, the cardiac lipid content
in the fasted state is relatively consistent between studies
with an average lipid/water ratio ranging from 0.3 to 0.6 %
[15, 31–34]. However, multiple physiological factors may
influence the abundance of this lipid pool, and it is crucial
to understand and acknowledge these sources of variation
as they may also impact on the quantifiable lipid levels in
cardiac disease.
The lipid content primarily depends on the feeding state.
In two independent studies, myocardial lipid content was
increased by 3- to fourfold, following a fasting period of 2
and 3 days, respectively [31, 35], whereas it increased by
only 55–70 % in the case of partial caloric restriction [35,
36]. This was associated with increases in plasma FFA
proportional to the degree of starvation [35]. Interestingly,
these changes in lipid metabolism are paralleled by an
impairment of diastolic function, correlating with the
increase in myocardial Tg content [35, 36].
Prolonged exercise also resulted in an increased Tg
storage in cardiac tissue (accompanied by a rise in plasma
FA levels), but this did not hamper systolic cardiac func-
tion as assessed by cine-MRI [34]. Conversely, 3 days on a
high-fat/high-energy diet did not induce any detectable
change in myocardial Tg content despite the significant
increases in post-prandial plasma triglyceride, FFA and
hepatic triglyceride content [37]. Differences in metabolic
state could explain why increased plasma FFA levels are
associated with an increase in myocardial Tg content in the
case of caloric restriction and not during caloric excess
[37].
The main determinant of myocardial Tg content is the
body mass index, and a good correlation between BMI and
Tg over a wide range of BMI has been demonstrated
(Fig. 3) [15, 38]. However, other factors may also con-
tribute to individual variations. Specifically, van der Meer
et al. [32] showed an increase in the Tg content in the
ageing heart, associated with the age-related decline in
diastolic function, which was independent of the BMI.
However, this finding was not confirmed in a different
study [38].
Obesity and type 2 diabetes mellitus
Obesity and its associated comorbidities, which include
type 2 diabetes mellitus, are reaching pandemic proportion
[39, 40]. They are referred to as the metabolic syndrome
and could result in a decrease in the life expectancy in the
21st century [41, 42]. Obesity (i.e., body mass index
(BMI) C 30 kg/m2), which is the consequence of an
imbalance between caloric intake and energy expenditure,
leads to triglyceride storage in organs other than adipose
tissue, such as muscle, liver, pancreas and also the heart.
The ectopic deposition of these lipid droplets in the cyto-
plasm results in cell dysfunction, a phenomenon called
lipotoxicity [42, 43].
Fig. 3 Correlation between myocardial lipid levels (L/W%) assessed
by 1H-MRS and BMI in healthy volunteers. Signal was acquired
within a single breath-hold from a 22 9 12–19 9 32–36 mm voxel
located in the interventricular septum using a STEAM pulse
sequence. (From [15]—reproduced with kind permission from John
Wiley and Sons)
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Despite this concept of fatty heart having been described
for the first time more than 300 years ago, its implications
on cardiac function were only appraised in the second half
of the 20th century with the development of echocardiog-
raphy [44, 45]. Alpert et al. [45] reported a correlation
between the increase in LV mass, decrease in systolic
function and impairment in diastolic filling observed in
morbidly obese patients and the duration of obesity.
Moreover, the large-scale Framingham study showed a
significant link between LV mass and BMI even after
adjustment for potential confounding factors such as age or
blood pressure [46–48].
In an animal model of obesity secondary to unrespon-
siveness to leptin, the ZDF rat, myocardial steatosis has
been associated with cardiac dysfunction secondary to
lipoapoptosis [48]. This fatty acid infiltration has also
commonly been observed in the non-ischaemic failing
heart of patients at the time of transplantation, particularly
in obese and diabetic people. Interestingly, this metabolic
dysregulation was accompanied with a distinct transcrip-
tional profile similar to the one observed in the ZDF hearts
[49].
CMR studies in obese patients can be hampered by
significantly reduced patient comfort due to the restricted
diameter of the magnet bore (typically in the order of
60 cm), which may result in a more frequent occurrence of
claustrophobia. Reduced sensitivity due to the increased
distance between receive coil-array and the heart, breathing
problems, affecting breath-hold, resulting in variable
breath-hold times, and/or ECG detachment due to sweating
may place additional constraints on the application of 1H-
MRS in this patient group. Nevertheless, 1H-MRS studies
have been feasible and have confirmed an increase in
myocardial lipid content in hearts of overweight and obese
subjects by up to threefold compared to lean individuals
[15, 16, 24]. This triglyceride overload was associated with
an increase in cardiac mass and a subtle impairment in
myocardial systolic thickening [16]. Following dietary
restriction in obese diabetic patients, myocardial triglyc-
eride content decreases, which was associated with an
improvement in diastolic function (E/A ratio) [35].
Improvement in cardiac function also paralleled the
decrease in cardiac Tg, following either a therapeutic
intervention (administration of trimetazidine [50, 51]) or
exercise [51].
The existence of a diabetic cardiomyopathy has been
recognised since 1972 [52]. While myocardial fatty acid
accumulation and the associated lipotoxicity seem to play a
role, the exact underlying aetiology is still incompletely
understood [53]. In a large human study using 1H-MRS,
McGavock et al. [33] showed that cardiac steatosis occurs
in patients with impaired glucose tolerance even before the
onset of type 2 diabetes mellitus and precedes cardiac
dysfunction. Another study compared patients with type 2
diabetes mellitus (T2DM) with controls of the same age
and BMI and showed that there is an increase in myocar-
dial triglyceride content in uncomplicated T2DM and is
associated with an impairment of LV diastolic function
[54]. These studies constitute the first step towards a better
understanding of diabetic cardiomyopathy in the human
heart, and, as stated by van de Weijer et al. [53], the
development of non-invasive techniques to assess cardiac
metabolism should bring an important contribution to this
field.
1H-MRS to assess cardiac lipid metabolism in pre-
clinical studies is still under-utilised despite its potential.
Bakermans et al. [55] have successfully applied the tech-
nique in transgenic mice deficient in long-chain acyl-CoA
dehydrogenase. These mice were characterised by
myocardial Tg accumulation (normal: 0.65 ± 0.16 %
of water signal; transgenic: 1.10 ± 0.20 %), which further
increased by 63 % upon fasting. Concomitantly, an
impairment in systolic and diastolic function was observed
in the fasted animals suggesting toxicity associated with
accumulating lipid metabolites.
Myocardial infarction
Changes in fatty acid metabolism occur following myo-
cardial infarction (i.e., temporary or permanent interruption
of the coronary blood supply). In the central zone of the
infarct, the drastic decrease in blood flow quickly leads to
cell death. However, in the border zone where blood flow
decreases less severely, cellular integrity is conserved and a
reduction in b-oxidation results in the accumulation of lipid
droplets within myocardial cells [56, 57]. Changes in lipid
content in this area-at-risk can be assessed by magnetic
resonance.
In canine hearts following 24-h coronary occlusion, lipid
content—measured ex vivo by high resolution 1H-NMR—
was increased in areas with moderate blood flow reduction
compared to control areas or areas with severe obstruction
[58]. Follow-up studies on the same model were performed
on the intact excised heart using cardiac spectroscopic
imaging and confirmed that triglycerides accumulate in the
area-at-risk, resulting in an increase by up to 10 times
compared to the remote zone [59, 60]. Finally, investigat-
ing the ‘‘stunned’’ canine myocardium induced by 15 min
of coronary occlusion followed by 3 h of reperfusion also
showed a twofold increase in NMR detectable lipid content
in the injured area [61].
Therefore, lipid accumulation may potentially represent
a clinical tool to assess the area-at-risk. However, this
requires excellent spatial localisation in order to reliably
assess cardiac lipids in a given cardiac area, which is
particularly problematic for the free wall due to the
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potential for signal contamination from the adjacent lipid-
rich pericardium.
Cardiomyopathy and heart failure
To date, only very few studies comprising small numbers
of patients have focused on lipid metabolism in cardio-
myopathy and heart failure. In a study on hypertrophic
cardiomyopathy (HCM), dilated cardiomyopathy (DCM)
and ischaemic cardiomyopathy, Nakae et al. [38] demon-
strated that there is no consistent effect of the size of the Tg
pool with cardiac dysfunction. Lipid concentration was
decreased in HCM and correlated with left ventricular
ejection fraction (LVEF), while there was a very wide
variation in DCM. In the latter, Tg content did not correlate
with cardiac dysfunction, but significantly with BMI. These
findings agree with the observations by Sharma et al. [49],
who found that, in the non-ischaemic cardiac HF model,
accumulation of lipids was most pronounced when heart
failure was associated with diabetes and obesity.
Creatine metabolism
In tissues with high and fluctuating energy demand such as
the heart, the creatine kinase (CK) system plays a crucial
role in the transport and buffering of high-energy phos-
phates from sites of production (i.e., mitochondria) to sites
of utilisation (i.e., myofibrils). CK catalyses the reversible
transfer of the c-phosphate group of ATP to creatine
yielding adenosine diphosphate (ADP) and phosphocrea-
tine. The latter serves as an energy carrier and reserve,
replenishing ATP levels and maintaining low ADP levels
in the vicinity of cellular ATPases.
Changes in high-energy phosphate metabolism occur in
the failing heart of humans and animals: a decrease in
phosphocreatine and total creatine by up to *60 % inde-
pendent of the underlying aetiology has been measured in
numerous studies and precedes the drop in ATP observed
in end-stage HF. These observations have been at the origin
of the energy-starvation hypothesis of the failing heart [62].
However, the exact role of creatine in the pathophysiology
of HF is still unclear, and determining this has so far been
hampered by a lack of sensitive, non-invasive techniques to
assess high-energy phosphate metabolism. The develop-
ment of MRS addresses this need, providing a window into
cardiac metabolism that has sparked renewed interest in
this field of cardiac research.
To date, more papers have reported on cardiac 31P-MRS
in vivo, while only a handful of studies used 1H-MRS. The
ratio of PCr/ATP is considered a sensitive indicator of the
metabolic state of the myocardium, as it decreases in
the hypertrophied and failing human and animal heart
[63–65]. Interestingly, it has also been shown to be a better
prognostic marker in patients with dilated cardiomyopathy
than the traditionally used New York Heart Association
class or LV ejection fraction [66]. However, this ratio
remains a surrogate of absolute measurement in the
absence of a widely available method to non-invasively
quantify PCr and ATP concentrations. In the presence of
reduced ATP levels, this factor will underestimate the true
extent of high-energy phosphate depletion. Moreover, in
the presence of heterogeneous cardiac disease, regional
variations have to be considered. Specifically, it has
recently been shown in a swine model of MI using 2D-CSI
that no ATP or PCr could be detected in the infarcted
tissue, whereas PCr/ATP was severely reduced in the
border zone compared to the remote zone [67].
1H-MRS allows the assessment of the total creatine pool
(sum of the free creatine and PCr). Hence, 31P-MRS and
1H-MRS provide complementary information, and, by
combining both techniques, a near complete profile of the
CK system can be obtained: 31P-MRS allows for direct
measurement of ATP & PCr levels, and 1H-MRS can
quantify total creatine [68], which enables the calculation
of ADP levels from the CK reaction equilibrium:
ADP½  ¼ ATP½   Free Cr½ ð Þ= PCr½   Hþ½   Keq
 
; ð1Þ
where Keq is the equilibrium constant of the reaction, and
[ADP], [ATP], [Free Cr], [PCr], [H?] indicate the con-
centrations in ADP, ATP, free creatine, phosphocreatine
and protons, respectively.
This approach represents, in principle, a unique oppor-
tunity to non-invasively measure in vivo the free energy
change of ATP hydrolysis (DG*ATP) available to drive
ATP-requiring reactions, according to the equation:
DGATP kJ/molð Þ ¼ DG þ RT ln ADP½   Pi½ = ATP½ ð Þ;
ð2Þ
where DG is the value of DG*ATP under standard con-
ditions of molarity, temperature, pH and Mg2?; R the
universal gas constant; T, the temperature (in Kelvin); and
[Pi], the concentration in inorganic phosphate.
Maintaining a high |DG*ATP| is essential for normal
myocyte function. Small changes in the free energy of ATP
hydrolysis would impede the activity of key intracellular
ATPases such as the sarco/endoplasmic reticulum Ca2?-
ATPase, the myosin ATPase or the Na?-K?-ATPase.
Ingwall and Shen [69] called energy reserve the difference
between the energy available from ATP hydrolysis and the
driving force required for the ATP-utilising reactions to
occur. In the failing heart or at high workloads, this energy
reserve might become critical for the reaction to occur.
Therefore, augmenting the high-energy phosphate metab-
olism could be an effective therapeutic strategy to support
the energy-starved failing heart, as recently demonstrated
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by Gupta et al. They showed that increasing ATP flux by
overexpressing the myofibrillar isoform of CK in mice,
improved contractile function and long-term survival fol-
lowing thoracic aortic constriction [5].
Acute myocardial ischaemia
Bottomley and Weiss [14] were first to use 1H-MRS to
measure total creatine in the human heart. After validation
of the technique in a canine model of myocardial infarction
[68], they measured in patients approximately threefold
decrease in creatine levels in the infarcted area compared
to the remote myocardium or healthy control [14, 68]. The
potential of 1H-MRS in assessing ischaemic myocardium
metabolism was also demonstrated by a study investigating
myocardial contractility. In patients with a stenosis of the
left anterior descending coronary artery of 50 % or more,
Nakae et al. [70] showed a decrease in total creatine levels
by about 40–50 % in the hypokinetic and akinetic regions
of the ischaemic myocardium, whereas in patients with no
wall motion abnormalities, creatine levels were compara-
ble to those measured in healthy controls. These results
confirm ex vivo NMR observations on tissue samples from
the infarcted canine heart, where creatine levels decreased
in proportion to the level of coronary flow reduction [58]
and suggest that 1H-MRS could be a suitable technique in
appraising myocardial viability in coronary artery disease.
Chronic heart failure
In a series of 1H-MRS studies, Nakae et al. [38, 71–73]
have shown a significant reduction in myocardial creatine
content in patients with heart failure secondary to non-
ischaemic diseases (dilated cardiomyopathy, hypertrophic
cardiomyopathy, cardiac amyloidosis or valvular heart
disease). All these studies were limited by the small
number of patients enrolled, which prevented a statistically
powerful individual analysis of each disease. However, the
importance of creatine depletion seemed to reflect the
severity of heart failure, and this was found to be inde-
pendent of the aetiology of HF (Fig. 4). Myocardial crea-
tine concentration correlated positively with cardiac
function (LVEF) [38, 71, 73] and free fatty acid uptake
[38] and negatively with plasma brain natriuretic peptides
(BNP) levels [71, 72]. Finally, total creatine levels could
potentially be predictive of subsequent heart failure; Nakae
et al. [73] showed that creatine levels had been lower in
patients who were later admitted to hospital for heart
failure in the year following the metabolic assessment
(11.3 ± 1.0 vs. 18.6 ± 5.9 lmol/l). However, these find-
ings need to be confirmed prospectively in larger studies
and compared with standard predictive markers. It also still
remains to be clarified whether this decrease in creatine
level contributes to the development of heart failure or
could constitute an adaptive process to maintain the ATP/
ADP ratio, thus preserving the chemical driving force of
ATPases [74, 75].
Understanding the role of creatine with transgenic
models
The exact role of creatine depletion and more broadly of
energy depletion in the pathophysiology of HF is still
unclear. Pharmaceutical inhibition and more recently
transgenic mouse models have provided a new opportunity
to study the specific roles of the different components of
the CK system. They also constitute an invaluable tool for
testing the hypothesis that enhancing (or preventing the
decline of) energy availability would improve cardiac
function in the failing heart.
To address this question, we sought to increase myo-
cardial creatine content. This cannot be achieved by dietary
creatine supplementation due to negative-feedback regu-
lation of creatine transporter activity, which provides tight
regulation of creatine levels in the heart [76]. To bypass
this mechanism, we have generated a transgenic mouse
model over-expressing the myocardial creatine transporter
(CrT-OE mice) [77], whose downregulation likely explain
the decrease in creatine content in the diseased myocar-
dium [78]. Using 1H-MRS and cine-MRI, creatine metab-
olism and cardiac function were monitored over 1 year in
these transgenic mice. We found a large variation in cre-
atine elevation between transgenic mice, which then
remained constant throughout an individual’s lifetime. To
our surprise, very high levels of myocardial creatine
(Fig. 5b) were associated with a progressive decline in
cardiac function during ageing, most likely due to reduced
glycolytic activity [79] and an inability to keep the total
creatine pool adequately phosphorylated [77]. However, it
remains to be tested whether a more modest increase in
intracellular creatine may yet be beneficial in chronic heart
failure. In an ongoing study, we are using 1H-MRS to
prospectively select CrT-OE mice with known creatine
levels prior to experimental myocardial infarction, an
approach that would not be possible using any other
technology.
Another approach is to study the hearts of mice with no
creatine. In a transgenic model (GAMT-KO) unable to
biosynthesise creatine, we confirmed non-invasively the
absence of creatine in the myocardium of these mice
(Fig. 5c) [17]. While the creatine-free GAMT-KO mice
had a mild cardiac phenotype under baseline conditions
(most likely due to compensatory mechanisms), they
exhibited a reduction in inotropic reserve and an enhanced
susceptibility to ischaemia/reperfusion [80]. Other experi-
mental designs become available by utilising longitudinal
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1H-MRS and creatine-deficient mice, such as withdrawal of
dietary creatine to determine kinetics of myocardial crea-
tine loss and creatine supplementation to determine whe-
ther the phenotype can be rescued.
Conclusion and future directions
Over the last decade, 1H-MRS has become an invaluable
technique to non-invasively assess cardiac lipid and to a
lesser extend creatine metabolism in clinical and pre-clin-
ical research; major findings are summarised in Table 1.
However, technical challenges, limited spatial and tempo-
ral resolution have hampered its widespread development,
especially as a clinical diagnostic tool. Both the use of
higher field strength magnets and advances in RF-coil
design and the development of more sophisticated motion-
compensation schemes (i.e., navigator techniques) com-
bined with advanced MRS-pulse sequences should signif-
icantly improve the robustness of the technique and allow
for shorter acquisition times [81]. This is a necessary
condition for proton (and other nuclei) spectroscopy to
become, in the future, an integral part of a standard CMR
protocol. Examination of regionally heterogeneous cardiac
Fig. 4 a0 shows a spectrum acquired from the interventricular septum
of a normal healthy volunteer (a). b0 shows a spectrum acquired from
the same location in a patient with advanced hypertrophic
cardiomyopathy (dilated phase). A decrease in the creatine peak
amplitude can be noted. (From [71]—reproduced with kind permis-
sion from Elsevier)
Fig. 5 1H-MRS spectra from the hearts of wild-type (a), creatine
transporter over-expressor (CrT-OE) (b) and guanidinoacetate
N-methyltransferase knock-out (GAMT-ko) (c) mice. The arrows
show the methyl resonance of creatine. Note the very high creatine
peak in the cardiac spectrum of the creatine transporter over-
expressor mouse compared to other resonances (b) and the lack of
creatine resonance in the GAMT-ko mouse (c)
Table 1 Summary of the major
sources of physiological
variation of myocardial lipid
and creatine levels
Lipids Creatine
Starvation * (correlates to degree of
starvation)
NA
Obesity * (correlates to BMI) NA
Diabetes mellitus type 2 * NA
Infarction * in area-at-risk ++ in infarcted area
Hypertrophic cardiomyopathy + shown in one study + proportional to cardiac dysfunction
Dilated cardiomyopathy No clear pattern + proportional to cardiac dysfunction
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pathologies such as ischaemic heart disease would also
clearly benefit from further development of magnetic res-
onance spectroscopic imaging techniques. Finally, for
MRS to expand beyond research, improvements in quan-
titative analysis of MR spectra are required, to provide
instantaneous robust results that can be interpreted by the
cardiologist. With these future developments in sight, MRS
will not only be established as an invaluable research tool
for the study of myocardial metabolism in animal models
of cardiovascular disease, but may also become more
widely used in clinical practice.
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